Case Reports in Medicine

Case Reports in Medicine / 2012 / Article

Case Report | Open Access

Volume 2012 |Article ID 976078 | 4 pages |

Computed Tomography and Magnetic Resonance Imaging Findings in a Case with Biliary Microhamartomas

Academic Editor: Gianfranco D. Alpini
Received24 Sep 2011
Accepted30 Oct 2011
Published31 Jan 2012


Biliary microhamartomas, also known as bile duct hamartomas and von Meyenburg complexes, are benign neoplasms containing cystic dilated bile ducts embedded in fibrous stroma. They develop in hepatobiliary system, do not generally give clinical outcomes, and are detected incidentally. However, they can rarely show malignant transformation. Our aim was to report the contribution of computed tomography, routine magnetic resonance imaging, and magnetic resonance cholangiopancreatography in the diagnosis of biliary microhamartomas in a 61-year-old woman.

1. Introduction

Biliary microhamartomas, also known as bile duct hamartomas and von Meyenburg complexes, develop in hepatobiliary system and do not generally give clinical outcomes. They are detected incidentally in most cases. Biliary microhamartomas are focal, disorderly collection of bile ducts that results from failure of involution of embryonic bile ducts [1]. They are benign neoplasms; however, they can rarely show malignant transformation [2]. Biliary microhamartomas are not uncommon. At autopsy, they were found in 5.6% of adults and in 0.9% of children [3]. Their incidence was reported as 0.6% in a serie including 2000 consecutive liver needle biopsies [4]. Our aim was to report the contribution of computed tomography (CT), routine magnetic resonance imaging (MRI), and magnetic resonance cholangiopancreatography (MRCP) in diagnosis of biliary microhamartomas.

2. Case Report

A 61-year-old, mildly obese woman with short stature was referred with right upper quadrant pain. The history of the patient was unremarkable, and she did not mention any medical or surgical illness. Laboratory examinations revealed hemoglobin (Hb): 13.6 g/dL, white blood cell (WBC): 7,100/mm³, serum albumin: 3.7 g/dL (N: 3.8–5.1 g/dL), alanine aminotransferase (ALT): 24 U/L (N: 0–31 U/L), alkaline phosphatase: 202 U/L (N: 0–240 U/L), gamma-glutamyl transferase (GGT): 24 U/L (N: 0–38 U/L). The patient was informed about the imaging procedures, and consent was obtained from her. All the procedures were performed according to the World Medical Association Declaration of Helsinki. Initially, we performed abdominal ultrasonography (US), but we were unable to demonstrate any prominent lesion in liver (Figure 1).

CT, routine MRI, and MRCP were performed afterwards. Contrast-enhanced CT revealed multiple, scattered, small, hypodense nodular lesions in liver parenchyma, measuring 1.5 cm or less in size (Figure 2).

On upper abdominal MRI, multiple, small, nodular lesions with slightly irregular contours in the liver parenchyma, measuring 1.5 cm or less in size, were detected. The lesions were hypointense on T1-weighted images and hyperintense on T2-weighted images. Diffusion-weighted images revealed no restriction of diffusion in the liver lesions. MRCP depicted an abundant number of hyperintense small lesions allover the liver which showed no association with the biliary system. The widths and contours of intrahepatic and extrahepatic bile ducts and pancreatic canal were normal on MRCP (Figure 3).

After making a detailed differential diagnosis, clinical and imaging findings were consistent with biliary microhamartomas, and the patient was included in a follow-up program to monitor the liver lesions.

3. Discussion

Biliary microhamartomas are tumor-like lesions of the liver [2]. Histologically, they are clusters of proliferated bile ducts lined by single layer of cuboidal cells embedded in fibrocollagenous tissue, and their size varies between 0.1 and 10 mm, but lesions measuring 1.5 cm in diameter can be demonstrated, as it was in the present case. Biliary microhamartomas do not generally give any symptoms [1, 5]. Adult polycystic liver disease (APLD) was reported to associate with biliary microhamartomas [1, 6]. With any imaging modality mentioned above, we could not be able to demonstrate larger and more numerous liver cysts which we are used to see in enlarged, diffusely cystic livers with APLD. But we decided to include the patient in a follow-up program to monitor the liver lesions.

US, CT, MRI, MRCP, and hepatobiliary scintigraphy (HBS) were used as imaging modalities in the diagnosis of biliary microhamartomas [79]. On US, the lesions can be seen as multiple, small, hypoechoic, or anechoic cystic lesions involving all segments. However, besides small cystic lesions, biliary microhamartomas can also be seen as hyperechogenic areas or lesions, and comet-tail artifacts may be seen posterior to the lesions [9, 10]. In the present case, US did not reveal any prominent lesion, suggesting that US may not be a suitable modality to show biliary microhamartomas. On CT, biliary microhamartomas are observed as multiple, round or irregular, small, hypodense lesions up to scattered throughout the liver on precontrast images. Luo et al. reported that on CT, lesions showed no enhancement, but increased in number by approximately 80–150% after administration of intravenous contrast medium [11]. On MRI, lesions appear hypointense and hyperintense on precontrast T1-weighted images and T2-weighted images, respectively. They show no communication with the biliary tree and demonstrate irregular delineation with no or slight rim enhancement following gadolinium administration [7].

In differential diagnosis, it is necessary to consider peribiliary cysts, simple hepatic cysts, autosomal dominant polycystic disease, metastatic liver disease, microabscesses, dilated biliary ducts, and Caroli’s disease [1, 8, 9, 12]. Peribiliary cysts are multiple, small, cystic dilatations of the intrahepatic extramural peribiliary glands, but they are located exclusively in the hepatic hilum and along the larger portal tract [13], which is different from the scattered distribution of biliary microhamartomas. Simple hepatic cysts are not as numerous and uniformly small as biliary microhamartomas. In autosomal dominant polycystic disease, cysts are usually larger and more numerous. Liver metastases are more variable in size, density, or signal intensity on CT and MRI [1]. MRI can aid in the differentiation of liver cysts (such as biliary microhamartomas) and liver metastases by identifying the hyperintense signal from liver cysts on heavily T2-weighted sequences [8]. Differentiation of biliary microhamartomas from microabscesses can generally be made clinically. Differentiation from dilated biliary ducts and Caroli’s disease can be made by looking at their association with biliary ducts using MRCP. Nuclear imaging can also be performed in differentiation of biliary microhamartomas from Caroli’s disease. In Caroli’s disease, HBS shows a particular pattern of cystic dilatation with accumulation of tracer in the intrahepatic ducts of the biliary tree [14]. Zheng et al. performed HBS in a case of biliary microhamartoma by using 99mTC-N-pyridoxy 1-5-methyl tryptophan (99mTC-PMT). HBS revealed that biliary system excreting function of radioisotope was normal and demonstrated normal appearances of biliary system without pooling areas [9] which helped to differentiate the entity from Caroli’s disease. In our case, since MRCP depicted bile ducts with their normal width, shape, and contours, we did not need to perform further imaging with HBS. We recommend the clinicians to use MRCP as an ultimate imaging modality to differentiate biliary microhamartomas from Caroli’s disease as we did in our case, but whenever they experience difficulty in diagnosis, we suggest that they can use HBS as a confirmative tool to solve the problem.

In conclusion, CT, MRI, and MRCP were useful in differentiating biliary microhamartomas from other cystic liver diseases and metastatic liver lesions in our case. Though biliary microhamartomas rarely show malignant transformation, this probability make radiological imaging of biliary microhamartomas necessary for early diagnosis.

Conflict of Interests

The authors declared that they have no conflict of interests.


This case report was presented in 16th Annual Meeting of Turkish Society of Magnetic Resonance, 19–21 May 2011, Istanbul.


  1. W. Dahnert, “Liver, bile ducts, pancreas and spleen,” in Radiology Review Manual, W. Dahnert, Ed., pp. 732–733, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 6th edition, 2007. View at: Google Scholar
  2. A. M. Xu, Z. H. Xian, S. H. Zhang, and X. F. Chen, “Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature,” European Journal of Gastroenterology and Hepatology, vol. 21, no. 5, pp. 580–584, 2009. View at: Publisher Site | Google Scholar
  3. M. S. Redston and I. R. Wanless, “The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected],” Modern Pathology, vol. 9, no. 3, pp. 233–237, 1996. View at: Google Scholar
  4. N. Thommesen, “Biliary hamartomas (von Meyenburg complexes) in liver needle biopsies,” Acta Pathologica et Microbiologica Scandinavica, vol. 86, no. 2, pp. 93–99, 1978. View at: Google Scholar
  5. G. Schneider, L. Grazioli, and S. Saini, “Imaging of the biliary tree and gallbladder diseaese,” in MRI of the Liver, G. Schneider, L. Grazioli, and S. Saini, Eds., p. 252, Springer, Milan, Italy, 2nd edition, 2006. View at: Google Scholar
  6. P. J. Karhunen, “Adult polycystic liver disease and biliary microhamartomas (von Meyenburg's complexes),” Acta Pathologica Microbiologica et Immunologica Scandinavica, vol. 94, no. 6, pp. 397–400, 1986. View at: Google Scholar
  7. B. Mortelé, K. Mortelé, P. Seynaeve, D. Vandevelde, M. Kunnen, and P. R. Ros, “Hepatic bile duct hamartomas (von Meyenburg complexes): MR and MR cholangiography findings,” Journal of Computer Assisted Tomography, vol. 26, no. 3, pp. 438–443, 2002. View at: Publisher Site | Google Scholar
  8. Y. Nagano, K. Matsuo, K. Gorai et al., “Bile duct hamartomas (von Mayenburg complexes) mimicking liver metastases from bile duct cancer: MRC findings,” World Journal of Gastroenterology, vol. 12, no. 8, pp. 1321–1323, 2006. View at: Google Scholar
  9. R. Q. Zheng, B. Zhang, M. Kudo, H. Onda, and T. Inoue, “Imaging findings of biliary hamartomas,” World Journal of Gastroenterology, vol. 11, no. 40, pp. 6354–6359, 2005. View at: Google Scholar
  10. M. Niizawa, M. Itoh, T. Mukojima, H. Ishida, and O. Masamune, “Sonographic features of von Meyenburg's complexes,” Journal of Clinical Ultrasound, vol. 19, no. 5, pp. 288–293, 1991. View at: Google Scholar
  11. T. Y. Luo, Y. Itai, N. Eguchi et al., “Von Meyenburg complexes of the liver: imaging findings,” Journal of Computer Assisted Tomography, vol. 22, no. 3, pp. 372–378, 1998. View at: Publisher Site | Google Scholar
  12. A. Principe, M. L. Lugaresi, R. C. Lords et al., “Bile duct hamartomas: diagnostic problems and treatment,” Hepato-Gastroenterology, vol. 44, no. 16, pp. 994–997, 1997. View at: Google Scholar
  13. Y. Nakanuma, M. Sasaki, T. Terada, and K. Harada, “Intrahepatic peribiliary glands of humans. II. Pathological spectrum,” Journal of Gastroenterology and Hepatology, vol. 9, no. 1, pp. 80–86, 1994. View at: Google Scholar
  14. R. Howman-Giles, R. Uren, E. Bernard, and S. Dorney, “Hepatobiliary scintigraphy in infancy,” Journal of Nuclear Medicine, vol. 39, no. 2, pp. 311–319, 1998. View at: Google Scholar

Copyright © 2012 Alper Dilli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1197 Views | 421 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.